Domestic and multinational pharmaceutical companies have begun countdowns in the DDP-4 type anti-diabetes treatment market

DDP-4 (dipeptidyl peptidase-4) inhibitors, leading the diabetes treatment market, are expected to be shaken. Launched of DPP-4 inhibitor-type new drugs, such as adjusted lineup extensions, will be made.

Although the only DDP-4 inhibitor-type new drug is the LG Life Sciences’ Zemiglo Tab, fierce competition is expected among domestic and multinational pharmaceutical companies in the domestic ma...